| --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | AmerisourceBergen is united in our responsibility to | | | | | | create healthier futures. | | | | | | AmerisourceBergen creates unparalleled access, efficiency, and reliability for ...

Acquisitions and Restructuring - The company acquired PharmaLex Holding Gmbh for €1.381 billion, with an additional €101 million paid due to subsequent acquisitions by PharmaLex[71] - Total acquisition, integration, and restructuring expenses for the three months ended December 31, 2022, were $37.236 million, compared to $32.334 million in the same period in 2021[80] - The company plans to change its name to Cencora in the second half of 2023, which will result in additional acquisition-related intangibles amortization expense[108] Financial Performance and Revenue - Revenue increased by 5.4% to $62.85 billion, driven by 6.1% growth in U.S. Healthcare Solutions, reaching $56.24 billion[111][112] - U.S. Healthcare Solutions gross profit rose by 8.4% to $1.39 billion, with a 5-basis point margin improvement to 2.46%[114][137] - International Healthcare Solutions revenue decreased by 0.6% to $6.61 billion, impacted by unfavorable foreign exchange rates and divestiture of Brazil specialty business[111][133] - Gross profit increased by 4.2% to $2.15 billion, supported by $49.9 million in antitrust litigation settlement gains[114][115][136] - Total segment operating income for the three months ended December 31, 2022, was $733.698 million, with gains from antitrust litigation settlements contributing $49.899 million[91] - U.S. Healthcare Solutions' operating income increased by $3.3 million, or 0.6%, to $572.4 million, with an operating income margin of 1.02%, a decline of 5 basis points due to increased operating expenses[142] - International Healthcare Solutions' operating income decreased by 10.4% to $161.3 million[142] - Total segment operating income decreased by 2.1% to $733.7 million[142] Operating Expenses and Costs - Total operating expenses increased by $96.9 million, or 6.8%, compared to the prior year quarter, primarily due to higher distribution, selling, and administrative expenses[109] - Distribution, selling, and administrative expenses increased by 10.3% to $1.29 billion, representing 2.05% of revenue[117][140] - LIFO expense of $25.1 million was recorded, driven by higher brand pharmaceutical inflation and inventory mix[139] Litigation and Liabilities - The company's accrued litigation liability related to the Distributor Settlement Agreement was $5.9 billion as of December 31, 2022, with $471.8 million expected to be paid before December 31, 2023[82] Foreign Exchange and International Operations - The International Healthcare Solutions segment's operating income decreased due to unfavorable foreign currency exchange rates in the current year quarter[109] - Operating income in International Healthcare Solutions decreased by 10.4% due to foreign exchange impacts and Brazil divestiture[122] Interest and Debt - The company has a $2.4 billion multi-currency senior unsecured revolving credit facility expiring in October 2027, with interest rates ranging from 80.5 to 122.5 basis points over SOFR/EURIBOR/CDOR/RFR[74] - Net interest expense decreased by 13.8% due to higher interest income from increased investment rates[123] - Net interest expense increased to $46.0 million, with a weighted average interest rate of 3.21% for interest expense and 2.86% for interest income[143] - Total debt as of December 31, 2022, was $5.64 billion, with $3.80 billion in additional availability under variable-rate debt facilities[155] - The company has a commercial paper program with an aggregate amount of up to $2.4 billion, fully backed by the Multi-Currency Revolving Credit Facility, with no borrowings outstanding as of December 31, 2022[156] Tax and Financial Metrics - Effective tax rate decreased to 19.8% from 24.6% due to non-U.S. income taxed at lower rates and stock-related tax benefits[124][130] - Days sales outstanding improved to 27.5 days, and days inventory on hand decreased to 27.4 days[129] Cash Flow and Investments - Cash and cash equivalents held by foreign subsidiaries increased to $830.6 million as of December 31, 2022, from $688.4 million as of September 30, 2022[147] - Net income for the period was $476.2 million, with positive non-cash items totaling $242.9 million, including $100.3 million in depreciation expense and $75.1 million in amortization expense[148] - The company expects to invest approximately $500 million in capital expenditures during fiscal 2023, focusing on technology initiatives and regulatory compliance[152] - Net cash used in financing activities included $807.2 million in purchases of common stock and $99.7 million in cash dividends paid on common stock[153]

Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," vari ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ | --- | --- | --- | --- | |------------------------------------------------------------|-------------------------------------------- ...

AmerisourceBergen Corporation (ABC) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Bennett Murphy - SVP, IR Steven Collis - Chairman, President & CEO James Cleary - EVP & CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co. Michael Cherny - Bank of America Merrill Lynch George Hill - Deutsche Bank Charles Rhyee - Cowen and Company Eric Percher - Nephron Research Eric Coldwell - Baird Kevin Caliendo - UBS Steven Valiquette - Barclays Bank A.J. Rice - Credit Sui ...

| --- | --- | |------------------|-------| | | | | November 3, 2022 | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware 2 ...

AmerisourceBergen Corporation (ABC) Q2 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President-Investor Relations Steve Collis - Chairman, President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Charles Rhyee - Cowen Steven Valiquette - Barclays Eric Percher - Nephron Research Eric Coldwell - Baird George Hill - Deutsche Bank Mic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware ...

| --- | --- | --- | --- | --- | |----------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Q1 FY2022 Financial Results February 2, 2022 | | | | | | | | | | | | | | | | | | | | | | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of ...